Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faropenem medoxomil versus placebo versus telithromycin for acute exacerbation of chronic bronchitis
2006-003944-42Phase 3Terminated
- Sponsor
- Replidyne, Inc.
- Start
- Jun 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) comparing Faropenem medoxomil, Placebo and Telithromycin (3 arms). Primary endpoints: Clinical response at Test-of-Cure versus placebo, Superiority of faropenem medoxomil versus placebo and 2 more. Started Jun 2007; status: terminated.
02
Drugs
faropenem medoxomiltelithromycin
03
Conditions
chronic bronchitis (CB)chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-003944-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003944-42.